|
US5007790A
(en)
|
1989-04-11 |
1991-04-16 |
Depomed Systems, Inc. |
Sustained-release oral drug dosage form
|
|
ES2124303T3
(es)
|
1992-03-25 |
1999-02-01 |
Depomed Inc |
Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
|
|
US5582837A
(en)
|
1992-03-25 |
1996-12-10 |
Depomed, Inc. |
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
|
|
AU3290397A
(en)
|
1996-06-10 |
1998-01-07 |
Depomed, Inc. |
Gastric-retentive oral controlled drug delivery system with enhanced retention properties
|
|
US5972389A
(en)
|
1996-09-19 |
1999-10-26 |
Depomed, Inc. |
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
|
|
WO1998055107A1
(en)
|
1997-06-06 |
1998-12-10 |
Depomed, Inc. |
Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
|
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
|
HK1050135A1
(zh)
|
1999-11-02 |
2003-06-13 |
Depomed, Inc. |
用於促进将药物给予胃的饭後模式药理学诱导
|
|
DE60123384T2
(de)
|
2000-02-04 |
2007-08-02 |
DepoMed, Inc., Menlo Park |
Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
|
|
US6488962B1
(en)
|
2000-06-20 |
2002-12-03 |
Depomed, Inc. |
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
|
|
US6451808B1
(en)
|
2000-10-17 |
2002-09-17 |
Depomed, Inc. |
Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
|
|
BR0116452A
(pt)
|
2000-12-21 |
2003-09-30 |
Glaxo Group Ltd |
Composto, composição farmacêutica, uso de um composto
|
|
MXPA03011096A
(es)
|
2001-05-29 |
2004-12-06 |
Depomed Dev Ltd |
Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
|
|
CA2409552A1
(en)
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
|
JP2005508358A
(ja)
|
2001-10-25 |
2005-03-31 |
デポメド・インコーポレイテッド |
胃滞留型ロサルタン投与量を用いる治療方法
|
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
|
WO2008080153A2
(en)
|
2006-12-22 |
2008-07-03 |
The Children's Hospital Of Philadelphia |
A novel protein kinase c therapy for the treatment of acute lung injury
|
|
US20110142837A1
(en)
*
|
2007-07-20 |
2011-06-16 |
Trustees Of The University Of Pennsylvania |
Method Of Treating Acute Respiratory Distress Syndrome
|
|
HRP20160625T1
(hr)
|
2007-09-10 |
2016-08-12 |
Boston Biomedical, Inc. |
Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
|
|
WO2009111648A1
(en)
|
2008-03-05 |
2009-09-11 |
Vicus Therapeutics, Llc |
Compositions and methods for mucositis and oncology therapies
|
|
JP5823672B2
(ja)
|
2009-07-27 |
2015-11-25 |
国立大学法人 新潟大学 |
受容体シグナル伝達阻害剤を含む脳梗塞治療用医薬品組成物
|
|
US8652476B2
(en)
|
2009-07-27 |
2014-02-18 |
Niigata University |
Pharmaceutical composition for treating ischemic events
|
|
US20120107304A1
(en)
*
|
2010-04-27 |
2012-05-03 |
Boehringer Ingelheim International Gmbh |
Combination therapy in treatment of oncological and fibrotic diseases
|
|
JP2014503500A
(ja)
|
2010-11-18 |
2014-02-13 |
シンタ ファーマスーティカルズ コーポレーション |
低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
|
|
RU2568258C2
(ru)
|
2011-02-28 |
2015-11-20 |
Саншайн Лейк Фарма Ко., Лтд |
Замещенные соединения хинолина и способы их использования
|
|
AU2012244549B2
(en)
|
2011-04-21 |
2017-04-20 |
Origenis Gmbh |
Heterocyclic compounds as kinase inhibitors
|
|
CA2852912A1
(en)
|
2011-10-31 |
2013-05-10 |
Glaxosmithkline Intellectual Property Limited |
Pazopanib formulation
|
|
US20130195871A1
(en)
|
2011-12-30 |
2013-08-01 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
WO2013148537A1
(en)
*
|
2012-03-29 |
2013-10-03 |
Ning Xi |
Substituted spirobicyclic compounds and methods of use
|
|
EP3782604A1
(en)
|
2013-07-31 |
2021-02-24 |
Windward Pharma, Inc. |
Aerosol tyrosine kinase inhibitor compounds and uses thereof
|
|
EP3046909A4
(en)
|
2013-09-17 |
2017-03-29 |
Pharmakea, Inc. |
Heterocyclic vinyl autotaxin inhibitor compounds
|
|
AU2014324566B2
(en)
*
|
2013-09-30 |
2019-01-24 |
The Texas A&M University System |
Compositions associated with and methods of managing neutrophil movement
|
|
WO2015111947A1
(en)
|
2014-01-24 |
2015-07-30 |
Lg Life Sciences Ltd. |
Composition for preventing or treating acute lung injury and acute respiratory distress syndrome
|
|
US20150299219A1
(en)
*
|
2014-04-22 |
2015-10-22 |
Calitor Sciences, Llc |
Bicyclic pyrazolone compounds and methods of use
|
|
RU2017105844A
(ru)
|
2014-08-08 |
2018-09-11 |
Форсайт Вижн4, Инк. |
Стабильные и растворимые составы ингибиторов рецепторных тирозинкиназ и способы их получения
|
|
US11166953B2
(en)
|
2017-04-17 |
2021-11-09 |
Yale University |
Compounds, compositions and methods of treating or preventing acute lung injury
|